You are here: Industry Insights > Market News > Granules India gets board nod to raise foreign investment limit

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Granules India gets board nod to raise foreign investment limit

financialexpressJuly 06, 2017

Tag: granules , foreign investment

Favorites

Granules India said its board has approved a proposal to increase the foreign investment limit in the company to 49 per cent.

The board of directors has agreed to increase the present limit of FII/ FPIs shareholding in the company to 49 per cent of the total paid-up equity share capital, Granules India said in a BSE filing.

However, it said, the decision would be subject to shareholders’ approval.

As on March 31, 2017, FPI holding in the company stood at 9.98 per cent. Other foreign nationals owned 0.06 per cent.

Previous:Zydus starts phase II trial of ZYAN1 for treating anaemia in patients with CKD

Next:Pain-free microneedle patch could help boost flu vaccination rates

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Granules India gets board nod to raise foreign investment limit | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

1-bromo-3-chloro-5,5-dimethylhydantoin Granules BCDMH CAS NO. 32718-18-6

Naproxen Enteric_coated micro Granules Capsules

1,3-dibromo-5,5-dimethylhydantoin DBDMH Granules CAS NO.77-48-5

Potassium Chloride Granules in sachet 1g/6g, 1.5g/10g

Diminazene aceturate and Phenazone and Vitamin B granules for injection

lower price 97.5%~102.0% White to off-white,granules or powder Cefoxitin sodium

Azithromycin Granules 100mg, 250mg

Factory price polymorph polymer filler PCL Polycaprolactone pellets microspheres granular granules M

Diminazene aceturate and Phenazone granules for injection

Compound salvia miltiorrhiza granules (Containing extract of Salviae Miltiorrhizae Radix et Rhizoma

Granules India gets board nod to raise foreign investment limit

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>